Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct‐acting antiviral therapies in the United States
- 9 November 2018
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 26 (3) , 350-361
Abstract
Summary: Direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection achieve high cure rates, reducing HCV‐related disease progression to cirrhosis and hepatocellular carcinoma. We aim to evaluate the impact of DAAs on US liver transplant (LT) waitlist outcomes. We retrospectively evaluated US adults (age ≥18) with and without chronic HCV listed for LT before and after the widespread use of sofosbuvir, allowing a 6‐month period after approval (Era 1: 1/1/2002‐5/31/2014 vs Era 2: 6/1/2014‐12/31/2016) using the United Network for Organ Sharing registry. Overall, LT waitlist survival and likelihood of receiving LT were evaluated with multivariate Cox regression models. From 2002 to 2016, 158 045 patients were listed for LT. While the number of patients listed for HCV has been decreasing since 2012, the proportion of HCV patients with concurrent HCC is increasing by 3.33% per year (R2: 0.99, P < 0.001 by simple linear regression). While there was no difference in likelihood of LT between HCV and non‐HCV patients, those listed in Era 2 had lower likelihood of LT (HR: 0.91, P < 0.001), more pronounced in the HCV cohort (HR: 0.83, P < 0.001) compared to the non‐HCV cohort (HR: 0.93, P < 0.001). Compared to non‐HCV patients, higher waitlist mortality was seen in HCV patients in Era 1 (HR: 1.08, P < 0.001) but not in Era 2 (HR: 1.02, P = 0.75). Since the introduction of DAAs for HCV treatment, number of patients with HCV listed for LT has declined. In the post‐DAA era, HCV patients on the LT waitlist had improved waitlist mortality.Keywords
Funding Information
- American Association for the Study of Liver Diseases
This publication has 22 references indexed in Scilit:
- Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United StatesClinical Gastroenterology and Hepatology, 2017
- Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapyHepatology, 2016
- Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertensionJournal of Hepatology, 2016
- Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infectionHepatology, 2016
- Model for end‐stage liver disease limbo, model for end‐stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantationLiver Transplantation, 2015
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma#*Liver Transplantation, 2012
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosisHepatology, 2012
- Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶Hepatology, 2010
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009